Unique ID issued by UMIN | UMIN000011675 |
---|---|
Receipt number | R000013652 |
Scientific Title | Improvement of bowel movement and fecal properties by the intake of Bacillus coagulans lilac-01-contained Okara powder |
Date of disclosure of the study information | 2013/09/07 |
Last modified on | 2015/09/24 15:51:18 |
Improvement of bowel movement and fecal properties by the intake of Bacillus coagulans lilac-01-contained Okara powder
Effect of Bacillus coagulans lilac-01 on bowel movement and fecal properties
Improvement of bowel movement and fecal properties by the intake of Bacillus coagulans lilac-01-contained Okara powder
Effect of Bacillus coagulans lilac-01 on bowel movement and fecal properties
Japan |
constipation
Gastroenterology |
Others
NO
The purpose is to evaluate the effects of Bacillus coagulans lilac-01 for bowel movement and fecal propertiesby double-blind, placebo-controlled test.
Efficacy
Confirmatory
Pragmatic
Phase III
questionnaire for defecatory conditions
VAS, fecal microbiota, fecal water content, fecal pH, fecal oeganic acid content, fecal ammonium, fecal substrate decomposition, fecal bile acid
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
NO
No need to know
2
Treatment
Food |
Intake 2 g of Okara powder contained Bacillus coagulans lilac-01 dairy for two weeks.
Intake 2 g of Okara powder (placebo food) dairy for two weeks.
20 | years-old | <= |
80 | years-old | > |
Male and Female
Subjects suffered from constipation
Subjects we obtained written informed
consent for participation in the study.
(1) Subjects with a history of
gastrointestinal cancer
(2) Subjects with serious disease
and infection
(3) Subjects with previous
gastrointestinal surgery
(4) Subjects with IBS
(5) Subjects with a history of allergy to
medicine and food, especially soy
bean.
(6) heavy smokers and alcohol addict and
subjects that spend irregular
lifestyle.
(7) Subjects who donate 200ml or more of
blood within 4 wks, or who donate
400ml or more of blood within 12 wks
before screening or subjects who
donate plasma or platelet within 4 wks
before supplementation started.
(8) There is possibility of the inside of
the present pregnancy or pregnancy, or
it is under breast-feeding.
(9) Subjects who participated in other
clinical trials within the past one
months before the start of this
clinical trial.
(10) Subjects whom the attending
physician judges to be an
inappropriate subject.
700
1st name | |
Middle name | |
Last name | Prof. Nishihira, Jun |
Hokkaido Information University
Department of Medical Management and Informatics
59-2, nishi-nopporo, ebetsu, 069-8585, Hokkaido
011-385-4411
nishihira@do-johodai.ac.jp
1st name | |
Middle name | |
Last name | Director of center. Nishihira, Jun |
Hokkaido Information University
Health Information Science Center
59-2, nishi-nopporo, ebetsu, 069-8585, Hokkaido
011-385-4430
nishihira@do-johodai.ac.jp
Hokkaido Information University
Hokkaido National Federation of Small Business Associations
Local Government
Japan
Aterio bio Co., Inc.
YES
01120159
Hokkaido National Federation of Small Business Associations
北海道情報大学 保健センター(北海道)
2013 | Year | 09 | Month | 07 | Day |
Published
http://www.ncbi.nlm.nih.gov/pubmed/25338680
Completed
2013 | Year | 08 | Month | 01 | Day |
2013 | Year | 09 | Month | 01 | Day |
2013 | Year | 10 | Month | 21 | Day |
2013 | Year | 09 | Month | 06 | Day |
2015 | Year | 09 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013652